Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Другие воспалительные полинейропатии (Хроническая воспалительная демиелинизирующая полирадикулонейропатия)

Список литературы

  1. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, Attarian S, Blomkwist-Markens PH, Cornblath DR, Eftimov F, Goedee HS, Harbo T, Kuwabara S, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Sommer C, Topaloglu HA. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep;26(3):242-268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. PMID: 34085743.
  2. Nevo Y, Pestronk A, Kornberg A.J, Connolly A.M, Yee W.C, Iqbal I, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology. 1996;47:98–102. https://doi.org/10.1212/wnl.47.1.98
  3. Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul Disord. 2000;10:398–406. https://doi.org/10.1016/s0960-8966(00)00119-x
  4. Rossignol E, D"Anjou G, Lapointe N, Haddad E, Vanasse M. Evolution and treatment of childhood chronic inflammatory polyneuropathy. Pediatr Neurol. (2007) 36:88–94. https://doi.org/10.1016/j.pediatrneurol.2006.09.012
  5. Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. (2010) 41:202–7. https://doi.org/10.1002/mus.21480
  6. Dalakas MC, Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7:507. https://doi.org/10.1038/nrneurol.2011.121
  7. Schneider-Hohendorf T, Schwab N, Uçeyler N, et al. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2012; 78:402. DOI 10.1212/WNL.0b013e318245d250
  8. Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin Neurol 2012; 32:187. https://doi.org/10.1055/s-0032-1329194
  9. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 2015; 86:973. https://doi.org/10.1136/jnnp-2014-309697
  10. Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50:621 PMID: 1186294 .
  11. Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2008; 38:1036. https://doi.org/10.1002/mus.21000
  12. Broers MC, Bunschoten C, Nieboer D, et al. Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. Neuroepidemiology 2019; 52:161. doi: 10.1159/000494291.
  13. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21(1):28-33. https://doi.org/10.1111/ene.12190
  14. Iijima M, Koike H, Hattori N, et al. Refractory Peripheral Neuropathy Study Group of Japan. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry. 2008;79(9):1040-1043. https://doi.org/10.1136/jnnp.2007.128132
  15. Rajabally YA, Simpson BS, Beri S, et al. Epidemiologic variability of chron- ic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39(4):432-438. https://doi.org/10.1002/mus.21206
  16. Chiò A, Cocito D, Bottacchi E, et al.; PARCIDP. Idiopathic chronic in- flammatory demyelinating polyneuropathy: an epidemiological study in It- aly. J Neurol NeurosurgPsychiatry. 2007;78(12):1349–1353. https://doi.org/10.1136/jnnp.2007.114868
  17. Łukawska M, Potulska-Chromik A, Lipowska M, et al. Pediatric CIDP: Diagno- sis and Management. A Single-Center Experience. Front Neurol. 2021;12:667378. https://doi.org/10.3389/fneur.2021.667378
  18. Sarıkaya Uzan G, Vural A, Yüksel D, et al. Pediatric-Onset Chronic Inflam- matory Demyelinating Polyneuropathy: A Multicenter Study. Pediatr Neu- rol. 2023;145:3-10. https://doi.org/10.1016/j.pediatrneurol.2023.0 4.018
  19. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflam- matory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol. 1999; 46(6):910-913. https://doi.org/10.1002/1531-8249(199912)46:6%3C910::AID-ANA14%3E3.0.CO;2-2
  20. Sotgiu S, Onida I, Magli G, et al. Juvenile Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology in Sardinia, Insular Italy. Neuropediatrics. 2021;52(1):56-61. https://doi.org/10.1055/s-00 40-1715626
  21. Majumdar A, Hartley L, Manzur AY, et al. A case of severe congenital chronic inflammatory demyelinating polyneuropathy with complete spontaneous remission. Neuromuscul Disord. 2004;14(12):818-821. https://doi.org/10.1016/j.nmd.200 4.0 9.003
  22. Silwal A, Pitt M, Phadke R, et al. Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neuromuscul Disord. 2018;28:757-765. https://doi.org/10.1016/j.nmd.2018.06.001
  23. Dalakas M.C., Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP // Nat. Rev. Neurol. 2011. Vol. 7. P. 507-517. https://doi.org/10.1038/nrneurol.2011.121
  24. Markowitz J.A., Jeste S.S., Kang P.B. Child neurology: chronic inflammatory demyelinating polyradiculoneuropathy in children. Neurology. 2008;71:e74–e78. https://doi.org/10.1212/01.wnl.0000336646.91734.b1
  25. Козырева А.А., Бембеева Р.Ц, Дружинина Е.С., Заваденко Н.Н., Колпакчи Л.М, Пилия С.В. Современные аспекты диагностики и лечения хронической воспалительной демиелинизирующей полинейропатии у детей. Журнал неврологии и психиатрии им. С. С. Корсакова 2024, т. 124, No2, с. 58–68 https://doi.org/10.17116/jnevro202412402158
  26. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south East England. J Neurol Neurosurg Psychiatry. 1999;66(5):677–680. https://doi.org/10.1136/jnnp.66.5.677
  27. Costello F, Lee AG, Afifi AK, Kelkar P, Kardon RH, White M. Childhood-onset chronic inflammatory demyelinating polyradiculoneuropathy with cranial nerve involvement. J Child Neurol. (2002) 17:819–23. https://doi.org/10.1177/088307380201701112
  28. Riekhoff AG, Jadoul C, Mercelis R, Cras P, Ceulemans BP. Childhood chronic inflammatory demyelinating polyneuroradiculopathy–three cases and a review of the literature. Eur J Paediatr Neurol. (2012) 16:315–31. https://doi.org/10.1016/j.ejpn.2011.12.003
  29. Bunschoten C, Jacobs BC, Van den Bergh PYK, et al. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol 2019; 18:784. https://doi.org/10.1016/s1474-4422(19)30144-9
  30. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry 2019; 90:125. doi: 10.1136/jnnp-2018-318714
  31. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinat- ing polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve. 1997;20:1569-1575. doi: 10.1002/(sici)1097-4598(199712)20:12<1569::aid-mus12>3.0.co;2-w.
  32. Hattori N, Misu K, Koike H, et al. Age of onset influences clinical fea- tures of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2001;184:57-63. https://doi.org/10.1016/s0022-510x(00)00493-7
  33. Stojkovic T, de Seze J, Hurtevent JF, Fourrier F, Vermersch P. Phrenic nerve palsy as a feature of chronic inflammatory demyelin- ating polyneuropathy. Muscle Nerve. 2003; 27:497-499. https://doi.org/10.1002/mus.10361
  34. Henderson RD, Sandroni P, Wijdicks EF. Chronic inflammatory demyelinating polyneuropathy and respiratory failure. J Neurol. 2005;252:1235-1237. https://doi.org/10.1007/s00415-005-0848-2
  35. Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda K. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;50:1179-1182. https://doi.org/10.1212/wnl.50.4.1179
  36. Yamamoto K, Watarai M, Hashimoto T, Ikeda S. Chronic inflamma- tory demyelinating polyradiculoneuropathy with autonomic involve- ment. Muscle Nerve. 2005;31:108-112. https://doi.org/10.1002/mus.20140
  37. Boukhris S, Magy L, Li Y, Debras C, Vallat JM. Autonomic nervous system involvement in chronic inflammatory demyelinating poly- neuropathy. Rev Neurol (Paris). 2005;161:1228-1231. doi: 10.1016/s0035-3787(05)85198-7.
  38. Ruts L, van Koningsveld R, van Doorn PA. Distinguishing acute- onset CIDP from Guillain-Barré syndrome with treatment related fluctuations. Neurology. 2005;65:138-140. https://doi.org/10.1212/01.wnl.0000167549.09664.b8
  39. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain- Barré syndrome. Neurology. 2010;74:1680-1686. https://doi.org/10.1212/wnl.0b013e3181e07d14
  40. Vinit Suri, Shishir Pandey,Jyoti Singh, Amarnath Jena. Acute-onset chronic inflammatory demyelinating polyneuropathy after COVID-19 infection and subsequent ChAdOx1 nCoV-19 vaccination. BMJ Case Rep. 2021; 14(10): e245816. https://doi.org/10.1136%2Fbcr-2021-245816
  41. Sudeep KC, Bansal A, Randhawa MS, et al. Recurrent Guillain-Barré syndrome: clinical profile and outcome. Indian J Pediatr. 2023. https://doi.org/10.1007/s12098-023-04746-y.
  42. Kuitwaard K, Van Koningsveld R, Ruts L, Jacobs BC, van Doorn PA. Recurrent Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2009; 80:56–9
  43. Verma A, Tandan R, Adesina AM, Pendlebury WW, Fries TJ, Bradley WG. Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. Acta Neurol Scand. 1990;81:516-521. https://doi.org/10.1111/j.1600-0404.1990.tb01011.x
  44. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diag- nosis, clinical variants, response to treatment and prognosis of chronic inflammatory. doi: 10.1111/j.1529-8027.2010.00251.x.
  45. Rotta FT, Sussman AT, Bradley WG, Ram Ayyar D, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2000;173(2):129–139. 89.  https://doi.org/10.1016/s0022-510x(99)00317-2
  46. Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54(3):615–620. https://doi.org/10.1212/wnl.54.3.615
  47. Larue S, Bombelli F, Viala K, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol. 2011;18:899-905. https://doi.org/10.1111/j.1468-1331.2010.03312.x
  48. Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin- associated glycoprotein paraprotein-associated peripheral neuropa- thies. Cochrane Database Syst Rev. 2016;10:CD002827. https://doi.org/10.1002/14651858.cd002827.pub4
  49. Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinat- ing neuropathy with persistent conduction block. Neurology. 1982; 32:958-964. https://doi.org/10.1212/wnl.32.9.958
  50. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demy- elinating sensory and motor neuropathy: the Lewis-Sumner syn- drome. Muscle Nerve. 1999;22:560-566. https://doi.org/10.1002/(sici)1097-4598(199905)22:5%3C560::aid-mus2%3E3.0.co;2-q
  51. van den Berg-Vos RM, van den Berg LH, Franssen H, et al. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology. 2000;54:26-32. https://doi.org/10.1212/wnl.54.1.26
  52. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain. 1996; 119:765-774. https://doi.org/10.1093/brain/119.3.765
  53. Van den Bergh PY, Thonnard JL, Duprez T, Laterre EC. Chronic demyelinating hypertrophic brachial plexus neuropathy. Muscle Nerve. 2000;23:283-288. https://doi.org/10.1002/(sici)1097-4598(200002)23:2%3C283::aid-mus23%3E3.0.co;2-q
  54. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778-783. https://doi.org/10.1136/jnnp.57.7.778
  55. Sabatelli M, Madia F, Mignogna T, Lippi L, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001;248:772-777. https://doi.org/10.1007/s004150170093
  56. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropa- thy. Report of a joint TF of the European Federation of Neurolog- ical Societies and the Peripheral Nerve Society—first revision. J Peripher Nerv Syst. 2010;15:295-301. https://doi.org/10.1111/j.1529-8027.2010.00290.x
  57. Pegati A, Boisseau W, Maisonobe T, et al. Motor chronic inflamma- tory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treat- ment. J Peripher Nerv Syst. 2020;25:162-170. https://doi.org/10.1111/jns.12380
  58. Eftimov F, Liesdek MH, Verhamme C, van Schaik IN, PREDICT Study Group. Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol. 2014;14: 72. https://doi.org/10.1186/1471-2377-14-72
  59. Oh SJ, Joy JL, Kuruoglu R. Chronic sensory demyelinating neuropa- thy: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992; 55:677-680. https://doi.org/10.1136/jnnp.55.8.677
  60. Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an underrecognized entity? Muscle Nerve. 2013;48:727-732. https://doi.org/10.1002/mus.23821
  61. Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as “chronic sensory demyelinating polyneuropathy”. Muscle Nerve. 1995;8:440-444. https://doi.org/10.1002/mus.880180411
  62. Thonnard JL, Detrembleur C, Van den Bergh PYK. Assessment of hand function in a patient with chronic sensory demyelinating neuropathy. Neurology. 1997;49:253-257. https://doi.org/10.1212/wnl.49.1.253
  63. van Dijk GW, Notermans NC, Franssen H, Wokke JH. Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long- term follow-up study. J Neurol. 1999;246:1134-1139. https://doi.org/10.1007/s004150050531
  64. Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJB. Chronic immune sensory polyradiculoneuropathy: a possibly treatable sensory ataxia. Neurology. 2004;63:1662-1669. https://doi.org/10.1212/01.wnl.0000142507.12763.58
  65. Rajabally YA, Wong SL. Chronic inflammatory pure sensory poly- radiculoneuropathy: a rare CIDP variant with unusual electrophysiology. J Clin Neuromuscul Dis. 2012;13:149-152. doi: 10.1097/CND.0b013e31822484fb.
  66. Clerici AM, Nobile-Orazio E, Mauri M, Squellati FS, Bono GG. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a longlasting case of chronic immune sensory polyradiculopathy. BMC Neurol. 2017;17:127. https://doi.org/10.1186/s12883-017-0906-2
  67. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating poly- radiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. J Peripher Nerv Syst. 2010;15:1-9. https://doi.org/10.1111/j.1529-8027.2010.00245.x
  68. Van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline  on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint TF of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. Eur J Neurol. 2010;17:356-363. doi: 10.1111/j.1468-1331.2009.02930
  69. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013;73:370-380. https://doi.org/10.1002/ana.23794
  70. Doppler K, Appeltshauser L, Wilhelmi K, et al. Destruction of para- nodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry. 2015;86:720-728. https://doi.org/10.1136/jnnp-2014-309916
  71. Miura Y, Devaux JJ, Fukami Y, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain. 2015;138:1484-1491. https://doi.org/10.1093/brain/awv054
  72. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014;82:879-886. https://doi.org/10.1212/wnl.0000000000000205
  73. Ogata H, Yamasaki R, Hiwatashi A, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015;2:960-971. https://doi.org/10.1002/acn3.248
  74. Devaux JJ, Miura Y, Fukami Y, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86:800-807. https://doi.org/10.1212/wnl.0000000000002418
  75. Cortese A, Lombardi R, Briani C, et al. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: clinical rele- vance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020;7: e639. doi: 10.1212/NXI.0000000000000639.
  76. Pascual-Goñi E, Fehmi J, Lleixà C, et al. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyneuropathy. Brain. 2021;144:1183-1196. doi: 10.1093/brain/awab014.
  77. Delmont E, Manso C, Querol L, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating poly- neuropathy. Brain. 2017;140:1851-1858. https://doi.org/10.1093/brain/awx124
  78. Stengel H, Vural A, Brunder A-M, et al. Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurol Neuro- immunol Neuroinflamm. 2019;6:e603. doi: 10.1212/NXI.0000000000000603.
  79. Vallat JM, Yuki N, Sekiguchi K, et al. Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti- neurofascin 155 antibodies. Neuromuscul Disord. 2017;27:290-293. https://doi.org/10.1016/j.nmd.2016.10.008
  80. Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology. 2018;4: 1051-1060. https://doi.org/10.1212/wnl.0000000000006625
  81. Querol L, Rojas-Garcia R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149. doi: 10.1212/NXI.0000000000000149.
  82. Nobile-Orazio E, Gallia F, Judica E. Chronic inflammatory demyelinating polyradiculoneuropathy and related disorders. In: Katirji B, Kaminsky HJ, Ruff RL, eds. Neuromuscular Disorders in Clinical Practice. 2nd ed. New York, NY: Springer; 2014:612-614.
  83. Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors- induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(suppl 2):S74-S85. https://doi.org/10.1111/jns.12339
  84. Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(suppl 2):S52-S62. https://doi.org/10.1111/jns.12338
  85. Van Nes, S.I. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies /S.I. Van Nes, E.K. Vanhoutte, P.A. van Doorn et al. // Neurology. – Vol. 76, № 4. – P. 337–345 https://doi.org/10.1212/wnl.0b013e318208824b
  86. Hughes, R. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy / R. Hughes, S. Bensa, H. Willison // Annals of Neurology. – 2001. – Vol. 50, № 2. – P. 195–201 https://doi.org/10.1002/ana.1088
  87. Супонева Н.А., Арестова А.С., Мельник Е.А., Зимин А.А., Зайцев А.Б., Якубу А., Щербакова Е.С., Юсупова Д.Г., Гришина Д.А., Гнедовская Е.В., Пирадов М.А. Нервно-мышечные болезни. 2023;13(1):68-74. https://doi.org/10.17650/2222-8721-2023-13-168-74
  88. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005;10:158-173. https://doi.org/10.1111/j.1085-9489.2005.0010206.x
  89. Dyck, P.J. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry / P.J. Dyck, W.R. Sherman, L.M. Hallcher et al. // Ann Neurol. – 1980. – Vol. 8, № 6. – P. 590–596. Валидация Шкалы оценки степени невропатических нарушений NIS выполнена на базе ФГБНУ НЦН (https://neurology.ru/o-centre/struktura/institut-neyroreabilitatsii-i-vosstanovitelnykh-tekhnologiy/gruppa validatsii-mezhdunarodnykh-shkal-i-oprosnikov/). https://neurology.ru/upload/medialibrary/52b/1bgw9fwrkrvi8ppmpw73jnepb2z4gsj0/SHkala-otsenki-stepeni-nevropaticheskikh-narusheniy-NIS.pdf
  90. Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical sig- nificance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010; 81:1194-1199. https://doi.org/10.1136/jnnp.2009.194324
  91. Vanhoutte EK, Latov N, Deng C, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG— the ICE study. Eur J Neurol. 2013;20:748-755. https://doi.org/10.1111/j.1468-1331.2012.03851.x
  92. Doneddu PE, Mandia D, Gentile F, et al. Home monitoring of main- tenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25: 238-246. https://doi.org/10.1111/jns.12396
  93. Allen JA, Pasnoor M, Dimachkie MM, et al. Quantifying treatment- related fluctuations in CIDP: results of the GRIPPER study. Neurol- ogy. 2021;96:e1876-e1886 https://doi.org/10.1212/wnl.0000000000011703
  94. Dyck PJ, Boes CJ, Mulder D, et al. History of standard scoring, nota- tion, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst. 2005;10:158-173. doi: 10.1111/j.1085-9489.2005.0010206.x.
  95. Vanhoutte EK, Latov N, Deng C, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG— the ICE study. Eur J Neurol. 2013;20:748-755. https://doi.org/10.1111/j.1468-1331.2012.03851.x
  96. Doneddu PE, Mandia D, Gentile F, et al. Home monitoring of main- tenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy. J Peripher Nerv Syst. 2020;25: 238-246. https://doi.org/10.1111/jns.12396
  97. Chhabra A, Carrino JA, Farahani SJ, Thawait GK, Sumner CJ, Wadhwa V, Chaudhary V, Lloyd TE. Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016 Dec;44(6):1513-1521. doi: 10.1002/jmri.25293. Epub 2016 Apr 29. PMID: 27126998.
  98. Zaidman C.M., Harms M.B., Pestronk A. Ultrasound of inherited vs. acquired demyelinating polyneuropathies. Neurol 2013;260(12):3115–21. DOI: 10.1007/ s00415-013-7123-8. PMID: 24101129. https://doi.org/10.1007/s00415-013-7123-8
  99. Sugimoto T., Ochi K., Hosomi N., Matsumoto M. Ultrasonographic diagnosis of inflammatory neuropathies. Brain Nerve 2014;66(3):223–8. PMID: 24607946.
  100. Наумова Е.С. Клинико-сонографическое исследование периферических нервов при дизиммунных и наследственных полинейропатиях . Автореферат дис. кандидата медицинских наук : 14.01.11. , 2018
  101. Chhabra A, Carrino JA, Farahani SJ, Thawait GK, Sumner CJ, Wadhwa V, Chaudhary V, Lloyd TE. Whole-body MR neurography: Prospective feasibility study in polyneuropathy and Charcot-Marie-Tooth disease. J Magn Reson Imaging. 2016 Dec;44(6):1513-1521. doi: 10.1002/jmri.25293. Epub 2016 Apr 29. PMID: 27126998.
  102. Sommer CL, Brandner S, Dyck PJ, et al. Peripheral Nerve Society guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst. 2010;15:164-175. https://doi.org/10.1111/j.1529-8027.2010.00276.x
  103. Garces-Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJ. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus neuropathy? Ann Neurol. 2011;69: 1043-1054. https://doi.org/10.1002/ana.22334
  104. Xu M, Pinto M, Sun C, et al. Expanded teased nerve fibre pathologi- cal conditions in disease association. J Neurol Neurosurg Psychiatry. 2019;90:138-140. https://doi.org/10.1136/jnnp-2018-319077
  105. Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65:1924-1929. https://doi.org/10.1212/01.wnl.0000188879.19900.b7
  106. Vallat JM, Tabaraud F, Magy L, et al. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evalu- ation of eight cases. Muscle Nerve. 2003;27:478-485. https://doi.org/10.1002/mus.10348
  107. Dalakas M.C., Medscape. Advances in the diagnosis, pathogenesis and treatment of CIDP // Nat. Rev. Neurol. 2011. Vol. 7. P. 507-517.
  108. Lehmann H.C., Burke D., Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment Journal of Neurology, Neurosurgery & Psychiatry 2019;90:981-987
  109. Куренков А.Л., Никитин С.С., Бурсагова Б.И., Кузенкова Л.М. Особенности хронической воспалительной демиелинизирующей полиневропатии у детей. Журнал «Нервно-мышечные болезни». 2012. №2. С. 40-51.
  110. Никитин С.С., Куренков А.Л. Особенности острой воспалительной и хронической демиелинизирующих невропатий у детей. В книге: Аутоиммунные заболевания в неврологии (под ред. И.А. Завалишина, М.А. Пирадова, А.Н. Бойко, С.С. Никитина, Н.Н. Спирина, А.В. Переседовой). Клиническое руководство. – Т. 2. – М.: РООИ «Здоровье человека», 2014. – С. 63-75.
  111. Куренков А.Л., Бурсагова Б.И., Кузенкова Л.М., Пак Л.А., Увакина Е.В. Хроническая воспалительная демиелинизирующая полинейропатия в детском возрасте: критерии диагноза и подходы к патогенетическому лечению. Фарматека. 2019. Т.26. №10. С.21-26.
  112. Ghaemi N., Hasanabadi H., Ashrafzadeh F., Sarvari S., Rahimi H., Hashemian S. Peripheral Neuropathy in Children and Adolescents with Insulin-dependent Diabetes Mellitus. Iran J Child Neurol. 2018 Spring;12(2):83-90
  113. Gorson K.C. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5(6):359-373.
  114. Azathioprine: Drug information (https://www.uptodate.com/contents/azathioprine-drug-information?topicRef=5265&source=see_link(
  115. Cyclosporine (ciclosporin) (systemic): Drug information (https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information?topicRef=9217&source=see_link#F8012602)
  116. Elena E Perez, MD, PhDNadine Shehata, MD, MSc, FRCPC Section Editor:Jordan S Orange, PhDDeputy Editors:Jennifer S Tirnauer, Anna M Feldweg, Intravenous immune globulin: Adverse effects (https://www.uptodate.com/contents/intravenous-immune-globulin-adverse-effects?topicRef=5265&source=see_link)
  117. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005 Dec;29(3):173-84
  118. Rajabally Y.A., Varanasi S. Practical electrodiagnostic value of F-wave studies in chronic inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2013;124(1):171-175.
  119. Nevo Y, Topaloglu H. 88th ENMC international workshop: childhood chronic inflammatory demyelinating polyneuropathy (including revised diagnostic criteria), Naarden, The Netherlands, December 8-10, 2000. Neuromuscul Disord. 2002 Feb;12(2):195-200
  120. McMillan HJ, Kang PB, Jones HR, Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord. 2013;23:103-111. https://doi.org/10.1016/j.nmd.2012.09.008
  121. Haliloğlu G, Yüksel D, Temoçin CM, et al. Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2016;26(12):817-824. https://doi.org/10.1016/j.nmd.2016.09.016
  122. Yang L. The diagnostic value of MRI in pediatric chronic inflammatory de- myelinating polyradiculoneuropathy. Brain Dev. 2016;38:173. https://doi.org/10.1016/j.braindev.2015.0 4.011
  123. Parikh S., Bernard G., Leventer R.J., van der Knaap M.S., van Hove J., Pizzino A., McNeill N.H., Helman G., Simons C., Schmidt J.L., Rizzo W.B., Patterson M.C., Taft R.J., Vanderver A.; GLIA Consortium. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015 Apr;114(4):501-515
  124. Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom. 2004 Winter;7(4):359-63.
  125. Laura K. Bachrach, Catherine M. Gordon et al. Bone Densitometry in Children and Adolescents. Pediatrics October 2016, 138 (4) e20162398
  126. McMillan H.J., Kang P.B., Jones H.R., Darras BT. Childhood chronic inflammatory demyelinating polyradiculoneuropathy: combined analysis of a large cohort and eleven published series. Neuromuscul Disord. 2013;23(2):103-111.
  127. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar;17(3):356-63.
  128. Mori M, Kuwabara S, Nemoto Y, Tamura N, Hattori T. Concomitant chronic inflammatory demyelinating polyneuropathy and myasthenia gravis following cytomegalovirus infection. J Neurol Sci. 2006 Jan 15;240(1-2):103-6.
  129. Richard A Lewis, Suraj Ashok Muley, Section Editor:Jeremy M Shefner, PhDDeputy Editor:Richard P Goddeau, Jr, DO, FAHChronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis A (https://www.uptodate.com/contents/chronic-inflammatory-demyelinating-polyneuropathy-etiology-clinical-features-and-diagnosis?source=history_widget#H3648072611)
  130. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):161-77.
  131. Dyck PJ, O"Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982 Feb;11(2):136-41.
  132. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Mar;9(3):245-53.
  133. Куренков А.Л., Бурсагова Б.И., Подклетнова Т.В., Абдуллаева Л.М. Хроническая воспалительная демиелинизирующая полиневропатия у детей: современные критерии установления диагноза и патогенетическое лечение. Неврологический журнал имени Л.О. Бадаляна. 2022; 3(2): 72–81. https://doi.org/10.46563/2686-8997-2022-3-2-72-81
  134. Sladky J.T. What is the best initial treatment for childhood chronic inflammatory demyelinating polyneuropathy: corticosteroids or intravenous immunoglobulin. Muscle Nerve. 2008;38:1638–1643
  135. Eftimov F., Winer J.B., Vermeulen M, de Haan R, van Schaik I.N. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013 Dec 30;12:CD001797
  136. Oaklander A.L., Lunn M.P., Hughes R.A., van Schaik I.N., Frost C., Chalk C.H.. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017;1(1):CD010369. Published 2017 Jan 13.
  137. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-845. https://doi.org/10.1002/ana.410360607
  138. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intrave- nous immunoglobulin for chronic inflammatory demyelinating poly- radiculoneuropathy. Cochrane Database Syst Rev. 2013;(12): CD001797. https://doi.org/10.1002/14651858.CD001797.pub3.
  139. Cianci P. et al. Subcutaneous immunoglobulin in infantile chronic inflammatory demyelinating polyneuropathy: A case report //Journal of Pediatric Neurosciences. – 2019. – Т. 14. – №. 1. – С. 38-41.MLA
  140. van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6:e590. https://doi.org/10.1212/nxi.0000000000000590
  141. Markvardsen LH, Debost JC, Harbo T, et al. Subcutaneous immunoglob- ulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2013;20:836-842 doi: 10.1111/ene.12080.
  142. Markvardsen LH, Sindrup SH, Christiansen I, et al. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: random- ized controlled trial study. Eur J Neurol. 2017;24:412-418. https://doi.org/10.1111/ene.13218
  143. Matsubayashi Tomo et al (2022) Experience with the use of subcutaneous immunoglobulin preparations for chronic inflammatory demyelinating polyneuritis in children. Brain Dev 54(2):132–134. https:// doi. org/ 10. 11251/ ojjscn. 54. 132
  144. Hughes R.A., Mehndiratta M.M., Rajabally Y.A. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;11(11):CD002062. Published 2017 Nov 29. doi:10.1002/14651858.CD002062.pub4
  145. Doneddu PE, Cocito D, Manganelli F, et al. Italian CIDP Database study group. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. J Neurol Neurosurg Psychiatry. 2019;90:125-132. https://doi.org/10.1136/jnnp-2018-318714
  146. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778-783. https://doi.org/10.1136/jnnp.57.7.778
  147. Pegat A, Boisseau W, Maisonobe T, et al. Motor chronic inflamma- tory demyelinating polyneuropathy (CIDP) in 17 patients: clinical characteristics, electrophysiological study, and response to treat- ment. J Peripher Nerv Syst. 2020;25:162-170. https://doi.org/10.1111/jns.12380
  148. Eftimov F, Liesdek MH, Verhamme C, van Schaik IN, PREDICT Study Group. Deterioration after corticosteroids in CIDP may be associ- ated with pure focal demyelination pattern. BMC Neurol. 2014;14: 72. https://doi.org/10.1186/1471-2377-14-72.
  149. Rafai MA, Boulaajaj FZ, Sekkat Z, El Moutawakkil B, Slassi I. Place des bolus de méthylprednisolone dans le traitement des polyradiculonévrites chroniques de l"enfant [Methylprednisolone pulse in treatment of childhood chronic inflammatory demyelinating polyneuropathy]. Arch Pediatr. 2010 Sep;17(9):1293-9. French. doi: 10.1016/j.arcped.2010.06.022
  150. Rafai MA, Moutaouakil F, El Otmani H, Fadel H, Boulaajaj FZ, El Moutawakil B, Gam I, Slassi I. Polyradiculonévrite chronique idiopathique de l"enfant: évolution sous bolus de méthylprednisolone [Chronic inflammatory demyelinating polyradiculoneuropathy in childhood: outcomes after methylprednisolone pulse therapy]. Rev Neurol (Paris). 2006 Jun;162(6-7):753-6. French. doi: 10.1016/s0035-3787(06)75075-5
  151. Куренков А.Л., Кузенкова Л.М., Никитин С.С., Бурсагова Б.И. Хроническая воспалительная демиелинизирующая полиневропатия у детей: диагностика и лечение. Вопросы современной педиатрии. 2014. Том 13. №5. – С. 34-41
  152. Chang SJ, Lee JH, Kim SH, Lee JS, Kim HD, Kang JW, Lee YM, Kang HC. Chronic inflammatory demyelinating polyneuropathy in children: a report of four patients with variable relapsing courses. Korean J Pediatr. 2015 May;58(5):194-8. doi: 10.3345/kjp.2015.58.5.194
  153. Mehndiratta M.M., Hughes R.A., Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;2015(8):CD003906. Published 2015 Aug 25.
  154. Dyck PJ, Daube J, O"Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461-465. https://doi.org/10.1056/nejm198602203140801
  155. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055-1066. https://doi.org/10.1093/brain/119.4.1055
  156. Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2015;2015(8):CD003906. https://doi.org/10.1002/14651858.cd003906.pub4
  157. Mörtzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54:2-15. https://doi.org/10.1016/j.transci.2016.01.003
  158. Mahdi-Rogers M., Brassington R., Gunn A.A., van Doorn P.A., Hughes R.A. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;5(5):CD003280. Published 2017 May 8
  159. Шевченко А. В. Хронические воспалительные демиелинизирующие полиневропатии у детей (клиника, диагностика, дифференциальная диагностика) : дис. – Российский Государственный Медицинский Университет, 2007.
  160. Bansal V.K., Meriggioli M.N. Immunotherapy in the treatment autoimmune neuromuscular disease. In book: Neuromuscular disorders in clinical practice (Eds. B. Katirji, H.J. Kaminski, R.L. Ruff). – New York: Springer, 2014. – P. 341-362.
  161. Козырева А.А., Бембеева Р.Ц., Дружинина Е.С., Заваденко Н.Н., Колпакчи Л.М., Пилия С.В. Современные аспекты диагностики и лечения хронической воспалительной демиелинизирующей полинейропатии у детей. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(2):58–68. https://doi.org/10.17116/jnevro202412402158
  162. Kyllerman M, Risberg K, Beckung E. Chronic inflammatory demyelinating polyneuropathy in children: follow-up investigation and results of prednisone-azathioprine treatment. Eur J PaediatrNeurol. (1999) 3:209–15. doi: 10.1016/S1090-3798(99)90083
  163. Rostasy KM, Diepold K, Buckard J, Brockmann K, Wilken B, Hanefeld F. Progressive muscle weakness after high-dose steroids in two children with CIDP. Pediatr Neurol. 2003 Sep;29(3):236-8. doi: 10.1016/s0887-8994(03)00222-4
  164. Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol. 2005 Nov;33(5):368-72. doi: 10.1016/j.pediatrneurol.2005.05.015
  165. Rodríguez Y., Vatti N., Ramírez-Santana C., Chang C., Mancera-Páez O., Gershwin M.E., Anaya J.M. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J Autoimmun. 2019 Aug;102:8-37
  166. Хайбуллин Т.И., Хабиров Ф.А., Аверьянова Л.А., Ахмедова Г.М., Бабичева Н.Н., Гранатов Е.В. Хроническая воспалительная демиелинизирующая полирадикулоневропатия и патогенетически близкие синдромы: диагностика и лечение Практическая медицина. 2014. № 2(78):21-30. http://pmarchive.ru/xronicheskaya-vospalitelnaya-demieliniziruyushhaya-poliradikulonevropatiya-i-patogeneticheski-blizkie-sindromy-diagnostika-i-lechenie/
  167. Гапешин Р.А., Баранцевич Е.Р., Руденко Д.И., и др. Современные представления о лечении хронической воспалительной демиелинизирующей полинейропатии (обзор литературы) // Ученые записки СПбГМУ им. И. П. Павлова. 2019. №1.
  168. Stevens, J. A. E., Llewelyn, G., & Hartley, L. Rituximab as an adjunct to intravenous immunoglobulin in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Paediatric Neurology, 21, e114. doi:10.1016/j.ejpn.2017.04.957
  169. Mara L. Becker, Dan Lovell, Steven J. Leeder, Chapter 12 - Pharmacology and Drug Therapy: Nonbiologic Therapies, Editor(s): Ross E. Petty, Ronald M. Laxer, Carol B. Lindsley, Lucy R. Wedderburn,Textbook of Pediatric Rheumatology (Seventh Edition), W.B. Saunders, 2016, Pages 140-160.e16, ISBN 9780323241458, https://doi.org/10.1016/B978-0-323-24145-8.00012-0.
  170. Grégoire MC, Finley GA. Drugs for chronic pain in children: a commentary on clinical practice and the absence of evidence. Pain Res Manag. 2013 Jan-Feb;18(1):47-50. doi: 10.1155/2013/402863. PMID: 23457686; (https://www.sciencedirect.com/science/article/pii/B9780323241458000120)
  171. de Leeuw TG, der Zanden TV, Ravera S, Felisi M, Bonifazi D, Tibboel D, Ceci A, Kaguelidou F, de Wildt SN, On Behalf Of The Gapp Consortium. Diagnosis and Treatment of Chronic Neuropathic and Mixed Pain in Children and Adolescents: Results of a Survey Study amongst Practitioners. Children (Basel). 2020 Nov 2;7(11):208. doi: 10.3390/children7110208. PMID: 33147808; PMCID: PMC7694093
  172. Garssen MP, Bussmann JB, Schmitz PI et al. Physical training and fatigue, fitness and quality of life in Guillain-Barre syndrome and CIDP. Neurology. 2004; 63(12): 2393–2395
  173. Graham RC, Hughes RA, White CM. A prospective study of physiotherapist prescribed community based exercise in inflammatory peripheral neuropathy. J. Neurol. 2007; 254(2): 228-235
  174. Markvardsen L. H., Overgaard, K., Heje, K., Sindrup, S. H., Christiansen, I., Vissing, J., & Andersen, H. Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. Muscle & Nerve. 2018; 57(1): 70-76
  175. Markvardsen LK, Carstens AR, Knak KL, Overgaard K, Vissing J, Andersen H. Muscle strength and aerobic capacity in patients with CIDP one year after participation in an exercise trial. J Neuromuscul Dis. 2019; 6(1):93-97. doi: 10.3233/JND-180344
  176. Janssen J, Bunce M, Nixon J, Dunbar M, Jones S, Benstead J et al. A clinical case series investigating the effectiveness of an exercise intervention in chronic inflammatory demyelinating polyneuropathy. Physiotherapy Practice and Research. 2018;39(1):37-44
  177. Селицкий М.М. Современные методы диагностики хронической воспалительной демиелинизирующей полиневропатии. Научно-практический терапевтический журнал. 4 (44). 2015. 36-42.
  178. Doneddu PE, Bianchi E, Cocito D, Manganelli F, Fazio R, Filosto M, Mazzeo A, Cosentino G, Cortese A, Jann S, Clerici AM, Antonini G, Siciliano G, Luigetti M, Marfia GA, Briani C, Lauria G, Rosso T, Cavaletti G, Carpo M, Benedetti L, Beghi E, Liberatore G, Santoro L, Peci E, Tronci S, Cotti Piccinelli S, Toscano A, Piccolo L, Verrengia EP, Leonardi L, Schirinzi E, Mataluni G, Ruiz M, Dacci P, Nobile-Orazio E; Italian CIDP Database Study Group. Risk factors for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): antecedent events, lifestyle and dietary habits. Data from the Italian CIDP Database. Eur J Neurol. 2020 Jan;27(1):136-143. doi: 10.1111/ene.14044
  179. Вакцинопрофилактика "Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок" (утв. Главным государственным санитарным врачом РФ от 9 января 2002 г.)
  180. Kuitwaard K., Bos-Eyssen M.E., Blomkwist-Markens P.H., van Doorn P.A. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. 2009;14(4):310-315

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*